Brokerages expect Halozyme Therapeutics, Inc. (NASDAQ:HALO) to post sales of $28.76 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Halozyme Therapeutics’ earnings. The highest sales estimate is $28.80 million and the lowest is $28.72 million. Halozyme Therapeutics posted sales of $29.57 million in the same quarter last year, which suggests a negative year-over-year growth rate of 2.7%. The business is expected to announce its next quarterly earnings report on Tuesday, May 8th.
On average, analysts expect that Halozyme Therapeutics will report full year sales of $28.76 million for the current year, with estimates ranging from $122.43 million to $125.73 million. For the next fiscal year, analysts forecast that the business will post sales of $173.35 million per share, with estimates ranging from $141.96 million to $204.74 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Halozyme Therapeutics.
Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.85 EPS for the quarter, topping the Zacks’ consensus estimate of $0.58 by $0.27. The firm had revenue of $189.60 million during the quarter, compared to the consensus estimate of $173.11 million. Halozyme Therapeutics had a return on equity of 89.83% and a net margin of 19.89%. The firm’s revenue was up 386.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.21) EPS.
Shares of Halozyme Therapeutics (NASDAQ HALO) traded up $0.15 on Wednesday, reaching $20.02. The company had a trading volume of 1,390,000 shares, compared to its average volume of 1,230,000. The company has a market cap of $2,850.00, a P/E ratio of 57.20 and a beta of 1.98. The company has a debt-to-equity ratio of 0.60, a quick ratio of 3.85 and a current ratio of 3.89. Halozyme Therapeutics has a 52-week low of $11.41 and a 52-week high of $21.13.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its holdings in shares of Halozyme Therapeutics by 6.6% during the third quarter. Rhumbline Advisers now owns 143,342 shares of the biopharmaceutical company’s stock valued at $2,490,000 after purchasing an additional 8,903 shares during the last quarter. Vanguard Group Inc. raised its position in Halozyme Therapeutics by 9.5% during the second quarter. Vanguard Group Inc. now owns 9,595,212 shares of the biopharmaceutical company’s stock valued at $123,010,000 after buying an additional 831,654 shares during the period. Alps Advisors Inc. raised its position in Halozyme Therapeutics by 10.7% during the third quarter. Alps Advisors Inc. now owns 139,764 shares of the biopharmaceutical company’s stock valued at $2,428,000 after buying an additional 13,556 shares during the period. Granite Investment Partners LLC raised its position in Halozyme Therapeutics by 44.7% during the third quarter. Granite Investment Partners LLC now owns 818,505 shares of the biopharmaceutical company’s stock valued at $14,217,000 after buying an additional 252,998 shares during the period. Finally, Legal & General Group Plc raised its position in Halozyme Therapeutics by 36.4% during the third quarter. Legal & General Group Plc now owns 60,157 shares of the biopharmaceutical company’s stock valued at $1,045,000 after buying an additional 16,041 shares during the period. 81.56% of the stock is owned by institutional investors and hedge funds.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.